Dermatology

The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

Ceramide-Containing Cleansers and Moisturizing Creams Plus Corticosteroids Have a Synergistic Treatment Effect For Atopic Dermatitis (Eczema)
What can we help you find?
[[thumbnail_alt_text]]
If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.
[[thumbnail_alt_text]]
Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.
[[thumbnail_alt_text]]
Tildrakizumab-asmn (Ilumya) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults.
[[thumbnail_alt_text]]
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.
[[thumbnail_alt_text]]
In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.
[[thumbnail_alt_text]]
Patients whose psoriasis covers a large percentage of their body face a significantly higher risk of death than those who do not have the disease, according to results of a recent study.
[[thumbnail_alt_text]]
The FDA has approved an updated label for Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL to include data in psoriasis involving the genital area.
[[thumbnail_alt_text]]
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.
[[thumbnail_alt_text]]
The FDA has approved ILUMYA (tildrakizumab-asmn, Sun Pharma) for treating adults with moderate-to-severe plaque psoriasis.